| Autor: |
Patel M; Department of Chemical & Physical Sciences, DuPont Merck Pharmaceutical Company, Wilmington, DE 19880-0500, USA., Kaltenbach RF 3rd, Nugiel DA, McHugh RJ Jr, Jadhav PK, Bacheler LT, Cordova BC, Klabe RM, Erickson-Viitanen S, Garber S, Reid C, Seitz SP |
| Jazyk: |
angličtina |
| Zdroj: |
Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 1998 May 05; Vol. 8 (9), pp. 1077-82. |
| DOI: |
10.1016/s0960-894x(98)00175-9 |
| Abstrakt: |
Cyclic urea SD146, a potent HIV protease inhibitor bearing a flat resistance profile, possessed poor solubility and bioavailability, which precluded further development of the compound. In an effort to improve upon the pharmacokinetic profile of the compound, several analogs modified at the P1/P1' residues were prepared and evaluated. Several of those compounds displayed significant improvement of physical properties. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect